Print
| DAY 1 | Auditorium |
|
| DAY 1 | Auditorium |
| ||
| 8:00 | 8:00: | |||
| 8:05: | 8:05: | |||
| 8:10: | 8:10: | |||
| 8:15: | Registration | 8:15: | ||
| 8:20: | 8:20: | |||
| 8:25: | 8:25: | |||
| 8:30: | 8:30: | |||
| 8:35: | 8:35: | |||
| 8:40: | 8:40: | |||
| 8:45: | 8:45: | |||
| 8:50: | 8:50: | |||
| 8:55: | 8:55: | |||
| 9:00 | Conference Welcome Chairs: Linda Sundström, AstraZeneca Fredrik Edfeldt, AstraZeneca |
9:00: | ||
| 9:05: | 9:05: | |||
| 9:10: | Therapeutic OLIGO profiling Chairs: Pär Matsson, University of Gothenburg Session Introduction 09:10 (5 mins) Pär Matsson, University of Gothenburg Antisense Based Therapeutics for the Treatment of Neurological Diseases 09:15 (45 mins) Frank Bennett, Ionis Pharmaceuticals |
9:10: | ||
| 9:15: | 9:15: | |||
| 9:20: | 9:20: | |||
| 9:25: | 9:25: | |||
| 9:30: | 9:30: | |||
| 9:35: | 9:35: | |||
| 9:40: | 9:40: | |||
| 9:45: | 9:45: | |||
| 9:50: | 9:50: | |||
| 9:55: | 9:55: | |||
| 10:00 | Refreshment Break | 10:00 | ||
| 10:05 | 10:05 | |||
| 10:10 | 10:10 | |||
| 10:15 | 10:15 | |||
| 10:20 | 10:20 | |||
| 10:25 | 10:25 | |||
| 10:30 | 10:30 | |||
| 10:35 | 10:35 | |||
| 10:40 | Therapeutic OLIGO profiling Chairs: Pär Matsson, University of Gothenburg In vitro Safety Assessment of Antisense Oligonucleotide Drugs 10:40 (30 mins) Sabine Sewing, Hoffmann-La Roche Harnessing RNA-protein binding for nucleic acids therapeutics design improvement 11:10 (30 mins) Alice Ghidini, Sixfold Technology Spotlight Partner 11:40 (5 mins) Vendor Sponsor, ELRIG Technology Spotlight Partner 11:45 (5 mins) Vendor Sponsor, ELRIG Revealing the intracellular concentration of nucleic-acid based therapeutics using NanoSIMS 11:50 (30 mins) Michael Kurczy, AstraZeneca |
10:40 | ||
| 10:45 | 10:45 | |||
| 10:50 | 10:50 | |||
| 10:55 | 10:55 | |||
| 11:00 | 11:00 | |||
| 11:05 | 11:05 | |||
| 11:10 | 11:10 | |||
| 11:15 | 11:15 | |||
| 11:20 | 11:20 | |||
| 11:25 | 11:25 | |||
| 11:30 | 11:30 | |||
| 11:35 | 11:35 | |||
| 11:40 | 11:40 | |||
| 11:45 | 11:45 | |||
| 11:50 | 11:50 | |||
| 11:55 | 11:55 | |||
| 12:00 | 12:00 | |||
| 12:05 | 12:05 | |||
| 12:10 | 12:10 | |||
| 12:15 | 12:15 | |||
| 12:20 | Refreshment Break with Poster Session (13:00 - 13:30) | 12:20 | ||
| 12:25 | 12:25 | |||
| 12:30 | 12:30 | |||
| 12:35 | 12:35 | |||
| 12:40 | 12:40 | |||
| 12:45 | 12:45 | |||
| 12:50 | 12:50 | |||
| 12:55 | 12:55 | |||
| 1:00 | 1:00: | |||
| 1:05: | 1:05: | |||
| 1:10: | 1:10: | |||
| 1:15: | 1:15: | |||
| 1:20: | 1:20: | |||
| 1:25: | 1:25: | |||
| 1:30: | Advancements in OLIGO design and synthesis Chairs: Shalini Andersson, AstraZeneca Session Introduction 13:30 (5 mins) Shalini Andersson, AstraZeneca Therapeutic siRNAs: how do we find the “best” ones? 13:35 (45 mins) Marie Wikstrom Lindholm, Silence Therapeutics Gmbh Charge neutral modifications to enhance the cell uptake and activity of exon-skipping oligonucleotides 14:25 (30 mins) Tom Brown, Oxford University Creating a comprehensive toolbox for oligonucleotide drug discovery 14:55 (15 mins) Lijuan Pang — WuXi AppTec Multiomics analysis of naturally efficacious lipid nanoparticle coronas reveals high-density lipoprotein is necessary for function 15:10 (10 mins) Kai Liu, AstraZeneca |
1:30: | ||
| 1:35: | 1:35: | |||
| 1:40: | 1:40: | |||
| 1:45: | 1:45: | |||
| 1:50: | 1:50: | |||
| 1:55: | 1:55: | |||
| 2:00 | 2:00: | |||
| 2:05: | 2:05: | |||
| 2:10: | 2:10: | |||
| 2:15: | 2:15: | |||
| 2:20: | 2:20: | |||
| 2:25: | 2:25: | |||
| 2:30: | 2:30: | |||
| 2:35: | 2:35: | |||
| 2:40: | 2:40: | |||
| 2:45: | 2:45: | |||
| 2:50: | 2:50: | |||
| 2:55: | 2:55: | |||
| 3:00 | 3:00: | |||
| 3:05: | 3:05: | |||
| 3:10: | 3:10: | |||
| 3:15: | 3:15: | |||
| 3:20: | Refreshment Break | 3:20: | ||
| 3:25: | 3:25: | |||
| 3:30: | 3:30: | |||
| 3:35: | 3:35: | |||
| 3:40: | 3:40: | |||
| 3:45: | 3:45: | |||
| 3:50: | 3:50: | |||
| 3:55: | 3:55: | |||
| 4:00 | Advancements in OLIGO design and synthesis Chairs: Shalini Andersson, AstraZeneca Tricyclo-DNA: promising antisense oligonucleotides for the treatment of neuromuscular diseases 16:00 (30 mins) Aurelie GOYENVALLE, Inserm - University of Versailles Choosing the right GMP partner for your CRISPR-enabled cell and gene therapy 16:30 (30 mins) Tal Shamia — Synthego Thermodynamic nearest-neighbor parameters for LNA/DNA PS-ASOs binding to RNA 17:00 (30 mins) Peter Hagedorn, Roche |
4:00: | ||
| 4:05: | 4:05: | |||
| 4:10: | 4:10: | |||
| 4:15: | 4:15: | |||
| 4:20: | 4:20: | |||
| 4:25: | 4:25: | |||
| 4:30: | 4:30: | |||
| 4:35: | 4:35: | |||
| 4:40: | 4:40: | |||
| 4:45: | 4:45: | |||
| 4:50: | 4:50: | |||
| 4:55: | 4:55: | |||
| 5:00 | 5:00: | |||
| 5:05: | 5:05: | |||
| 5:10: | 5:10: | |||
| 5:15: | 5:15: | |||
| 5:20: | 5:20: | |||
| 5:25: | 5:25: | |||
| 5:30: | 5:30: | |||
| 5:35: | 5:35: | |||
| 5:40: | 5:40: | |||
| 5:45: | 5:45: | |||
| 5:50: | 5:50: | |||
| 5:55: | 5:55: | |||
| 6:00 | 6:00: | |||
| 6:05: | 6:05: | |||
| 6:10: | 6:10: | |||
| 6:15: | 6:15: | |||
| 6:20: | 6:20: | |||
| 6:25: | 6:25: | |||
| 6:30: | 6:30: | |||
| 6:35: | 6:35: | |||
| 6:40: | 6:40: | |||
| 6:45: | 6:45: | |||
| 6:50: | 6:50: | |||
| 6:55: | 6:55: | |||
| 7:00 | 7:00: |